Reports about: RVNC
Short RVNC. How Revance Is Misleading Investors About RT002
November 20, 2015
Summary Revance has soared 50% to all-time highs based on preliminary data from a Phase 2 study, which appeared to indicate that its RT002 was superior to Allergan’s Botox. Revance...